Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2010
10/26/2010US7820697 1-Oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline; treatment of cancers, rheumatoid arthritis, inflammatory bowel disease, muscular dystrophy, Crohn's disease and viral disease
10/26/2010US7820696 Compounds and methods for controlling fungi, bacteria and insects
10/26/2010US7820695 Selective serotonin receptor inverse agonists as therapeutics for disease
10/26/2010US7820694 Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis
10/26/2010US7820693 2-Oxo-3-[1-oxo-3-(2-trifluoromethylphenyl)-1,2-dihydroisoquinolin-7-yl]oxazolidin-5-ylmethyl(2-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}ethoxy)acetate; 7-(2-Oxoazetidin-1-yl)-3-(2-trifluoromethylphenyl)-2H-isoquinolin-1-one; anticarcinogenic agent ( solid cancer)
10/26/2010US7820692 Tetrahydro isoquinoline derivatives, preparation methods and medicinal uses thereof
10/26/2010US7820691 Indoloquinoline compounds as calcium channel blockers
10/26/2010US7820690 Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
10/26/2010US7820689 treating in-stent restenosis, atherosclerosis, by administering dextromethorphan, naloxone, and/or naltrexone
10/26/2010US7820688 one effecting opioid analgesia and one effecting local anesthesia, in amounts sufficient to potentiate an antinociceptive response when both compounds are topically administered in a physiologically acceptable topical excipient
10/26/2010US7820687 inflammatory diseases such as asthma, Alzheimer's disease, atherosclerosis, diabetes, autoimmune diseases, tumor metastasis and myocardial ischemia; improved bioavailability; 2-(2-(diethylamino)-5-(N-isopropylmethylsulfonamido)pyrimidin-4-ylamino)-3-(4-(pyrrolidine-1-carbonyloxy)phenyl)propanoic acid
10/26/2010US7820686 Therapeutic agent for inflammatory bowel disease
10/26/2010US7820685 inhibitors of Aurora protein kinases; antiproliferative agents; melanoma, myeloma, leukemia, lymphoma, neuroblastoma, and cancer; N-(4-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-chloropyrimidin-2-ylthio)phenyl)cyclopentanecarboxamide
10/26/2010US7820684 Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same
10/26/2010US7820683 N-(2-hydroxyethyl)-N-methyl-2-[(4-{[1-(pyridin-2-ylmethyl)-1H-indazol-5-yl]amino}quinazolin-5-yl)oxy]propanamide for example; anticancer, antitumor agents
10/26/2010US7820682 3-{[(3R)-1-(3,5-dimethoxy-4-methylbenzoyl)-5-(2-phenylethyl)-3-pyrrolidinyl]oxy}benzoic acid methyl ester; treatment of urinary system disease; anticarcinogenic agent, antiarthritic agent, treats proliferative disease, inflammation/immune system disease, Sjogren*s syndrome, brain-related disease
10/26/2010US7820681 Methods for concomitant administration of colchicine and a second active agent
10/26/2010US7820680 HIV integrase inhibitors
10/26/2010US7820679 N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-′1,3,4-oxadiazol-2-yl-phenyl)pyridine-3 sulphonamide as an anticancer agent
10/26/2010US7820678 Pyrazinoylguanidine derivatives target the kidney; cardiovascular disease; for treating diseases characterized by too little liquid on mucosal surfaces, increase potency, reduced mucosal absorption, and slow dissociation; long half-life on mucosal surfaces
10/26/2010US7820677 for treatment of serotonin-related disorder, particularly 5-HT2C receptor related ( type II diabetes and obesity)
10/26/2010US7820676 Diketopiperazine salts for drug delivery and related methods
10/26/2010US7820675 Benzofuran compounds
10/26/2010US7820674 Especially 1-(5-((R)-2-Amino-1-phenylpropan-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-4-butylpiperazine-2,3-dione or derivatives; amyloid precursor protein-cleaving enzyme
10/26/2010US7820673 Urea derivative, process for producing the same, and use
10/26/2010US7820672 3-[5-chloro-6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-4-( 1H-indol-3-yl)-pyrrole-2,5-dione; T lymphocytes, Protein Kinase C (PKC) and glycogen synthase kinase 3 beta (GSK3B) mediated diseases;
10/26/2010US7820671 Peptidomimetic protease inhibitors
10/26/2010US7820670 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
10/26/2010US7820669 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors
10/26/2010US7820668 POLY/ADP-RIBOSE/ POLYMERASE (PARP) inhibitors; for treating neural tissue damage resulting from ischemia and reperfusion injury, depression, arthritis, inflammatory bowel disorders, gout, chronic pain, acute pain, neuropathic pain, renal failure, retinal ischemia, and septic shock; antitumor agents
10/26/2010US7820667 via nitric oxide synthase inhibitors such as (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin; side effect reduction
10/26/2010US7820666 Tetrahydrotriazolopyrazine derivatives and uses thereof
10/26/2010US7820665 phosphatidyl inositol 3-kinase inhibitors such as N-(6-(6-Chloro-5-(3-(difluoromethoxy)phenylsulfonamido)pyridin-3-yl)-3-(pyridin-4-yl)imidazo[1,2-b]pyridazin-2-acetamide
10/26/2010US7820664 N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents
10/26/2010US7820663 such as alpha -[(3-azabicyclo[3.3.0]octyl-3-amino)methylene]-N-(4-chlorophenyl)-3-methyl-5-isoxazoleacetamide, allosteric modulators of alpha 7 nicotinic acetylcholine receptor; central nervous system disorders, sleep disorders, neurodegenerative disorders
10/26/2010US7820662 IGF-1R enzyme inhibitor; antiproliferative, anticarcinogenic, antiinflammatory agent, antiallergen; psoriasis, asthma, disease and conditions of the immune system and central nervous system; better selectivity or potency, reduced toxicity, or fewer side effects
10/26/2010US7820661 prostaglandin EP2 receptor agonists for treating baldness, glaucoma, post-surgical and post-laser trabeculectomy ocular hypertensive episodes, inflammatory bowel disease, and as presurgical adjuncts
10/26/2010US7820660 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
10/26/2010US7820659 (R)-3-(3,5-Dichloro-4'-morpholin-4-yl-biphenyl-4-ylmethyl)-1-(4,5,6,7-tetrahydro-1H-benzoimidazol-5-yl)-pyrrolidin-2-one for treating diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome
10/26/2010US7820658 such as 2-Amino-4-phenyl-thieno[2,3-d]pyrimidine-6-carboxylic acid ethylamide; veterinary medicine; anticancer agents
10/26/2010US7820657 receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors
10/26/2010US7820656 for lowering blood glucose levels; insulin resistance; for use in drugs, foods, and beverages
10/26/2010US7820655 Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives
10/26/2010US7820654 such as 1-[2-(3-Chloro-4-methoxy-phenylamino)-6-phenyl-pyrimidin-4-yl]-piperidin-4-ol for treating atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by low expression of Perlecan
10/26/2010US7820653 includes Diels-Alder adduct which is a polycyclic aromatic compound (pentacene) with dienophile such as N-sulfinyl-R-sulfonamide; organic thin film transistors; for plastic substrates; electronics; low cost
10/26/2010US7820652 administering in ascending doses; used to treat bacterial infections and diseases related to infection; adverse side effect reduction
10/26/2010US7820651 for catheter and port systems, for preventing infections and sepsis
10/26/2010US7820650 active mainly against dermatophytes
10/26/2010US7820648 Inhibitors of the FAK (focal adhesion kinase) protein tyrosine kinases, antiproliferative, antitumor; for example 5-{4-[(1-Hydroxy-cyclopentylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one
10/26/2010US7820646 Anticancer agents; antiproliferative agents; using an substituted aimidazole compound
10/26/2010US7820645 Crystalline forms
10/26/2010US7820644 Substituted porphyrins
10/26/2010US7820643 Therapeutic treatment by administering milnacipran, a new use of existing pharmaceutical
10/26/2010US7820642 Nandrolone 17β-carbonates
10/26/2010US7820641 Bactericides; antitumor agents; moderators of gene expression; viricides; parasiticides; malaria therapy
10/26/2010US7820640 administering mixture of allopurinol, ebselen and n-acetylcysteine
10/26/2010US7820639 glycerol, dextran, chondroitin sulfate, water, and buffer; for treating corneal edema, for accompanying corneal transplantation and refractive corneal surgery
10/26/2010US7820638 Method of applying hyaluronic acid to implant or graft to enhance lubricity and cellular density
10/26/2010US7820637 Use of 5′-methylthioadenosine (MTA) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection
10/26/2010US7820636 purine base or a salt thereof for preparing a promoter for saccharide uptake in epidermal keratinocytes
10/26/2010US7820635 Therapy for cancer; Alzheimer's disease; using Rna sequences; control degradation , block translation of messenger Rna ; transcription product of target gene encoding clusterin
10/26/2010US7820634 contacting cells in vivo with composition comprising collagenous matrix of submucosa tissue delaminated from both tunica muscularis and luminal portion of tunica mucosa of warm-blooded vertebrates, and added exogenous deoxyribonucleic acid
10/26/2010US7820633 cytotoxic T-cell mediated killing of disease cells that express a weakly immunogenic or non-immunogenic cell-associated polypeptide antigen in an animal by administering a cytotoxic T-cell epitope and a T-helper lymphocyte
10/26/2010US7820632 For inhibiting expression of human immunodeficiency virus (HIV); for use in vitro/vivo
10/26/2010US7820631 For prophylaxis and therapy of viral infection for example by varicella zoster virus (VZV)
10/26/2010US7820630 Substituted indole-O-glucosides
10/26/2010US7820629 L- alpha -dioleoyl phosphatidyl{14-N-(1-deoxylactito-1-yl)amino-3,6,9,12-tetraoxa}tetra decanol; 2-O-{2-N-(1-deoxylactito-1-yl)aminoethyl} carbamoyl-1,3-O-dioleoyl glycerol; galactose, a suitable spacer and a certain lipid, a drug carrier; efficiently transferred into the liver
10/26/2010US7820628 Tumor lesion regression and conversion in situ into autologous tumor vaccines by compositions that result in anti-Gal antibody binding
10/26/2010US7820627 with core structure of pentaerythritol used as replacement for sugars; immunomodulators; immunogens within liposomes; tumor antigens; for use as haptens, inhibitors of bacterial-host cell adhesion; septic shock
10/26/2010US7820626 such as vulvodynia via comprising administering polyarginine; for treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing agents
10/26/2010US7820618 Improved lactate (leucine, arginine, methyl pyruvate, and methyl succinate) usage is accomplished through lactate precursors, adrenergic receptor agonists and insulinotropic agents
10/26/2010US7820594 agricultural fungicide or herbicide; fatty acids with another synergistic organic acid; emulsifierl; amino acid
10/26/2010US7820407 Heterologous proteins for use in enhancement of food products and pharmaceuticals; genetically modified Thraustochytriales microorganism for producing short chain fatty acids by a biosynthetic process
10/26/2010US7820375 Use of a protein of the CRMP family for treating diseases related to the immune system
10/26/2010US7820206 Modulating the inflammatory response in target cells by contacting the cells with a compund selected from dihydro-isohumulone, dihydro-isocohumulone, dihydro-isoadhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-isoadhumulone, hexahydro-isohumulone; cyclooxygenase inhibitors
10/26/2010US7820204 Drug delivery system targeting to estrogen receptor over-expressed cells
10/26/2010US7820203 Modified release dosage forms of skeletal muscle relaxants
10/26/2010US7820199 for therapy of allergic and/or inflammatory conditions of the skin and airway passages; desloratadine-pseudoephedrine once-a-day product which produces a release rate profile for pseudoephedrine over an extended period in excess of twelve hours while maintaining delivery of desloratadine
10/26/2010US7820197 Using bisphosphonic acid compound; mixture with solubilizer; permeability through skin
10/26/2010US7820196 Alleviating acute alcohol intoxication/side effects of a hangover by administering, for example, 2,3-dimercapto-1-propanol; food additives/supplements; animal feed; oxidation resistance; immunostimulants; demetallization; shelf life cosmetology; dermatology; food additives/supplements; feeds; drugs
10/26/2010US7820194 Combinations of viscoelastics for use during surgery
10/26/2010US7820193 Anticancer agents; prevent forming blood vessels; removal blockage
10/26/2010US7820186 For prophylaxis and therapy of cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne; stability; FDA Orange book listed patent for adapalene and benzoyl peroxide
10/26/2010US7820178 VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents
10/26/2010US7820169 inhibiting the activity of tumor necrosis factor TNF in a patient having rheumatoid arthritis or psoriatic arthritis, by administering a composition comprising an effective amount of human anti-TNF antibody comprising a heavy chain variable region comprising SEQ ID NO:7 and a light chain variable
10/26/2010US7820159 Using epidermal growth factor receptor as tool in identifying modulators for prevention and treatment of cell proliferative disorders
10/26/2010US7820154 Use of IL-1 antagonists to treat gout
10/26/2010US7820153 repelling organisms undesirable to plants such as aphids or beetles comprising exposing the plant to cis-jasmone
10/26/2010CA2661573C Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
10/26/2010CA2646756C Method of forming an aerosol for inhalation delivery
10/26/2010CA2598725C Fused aromatic compounds having anti-diabetic activity
10/26/2010CA2584622C Pharmaceutical formulation for increasing solubility of 10-hydroxycamptothecin compounds in non-aqueous polar solvents
10/26/2010CA2565813C Substituted methyl aryl or heteroaryl amide compounds
10/26/2010CA2564684C Use of thioxanthene derivatives as chemosensitising compounds
10/26/2010CA2543650C A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing thesame
10/26/2010CA2533583C N-desmethyl-n-substituted-11-deoxyerythromycin compounds
10/26/2010CA2526893C Inhibition of the expression of huntingtin gene
10/26/2010CA2516438C Treatment of inflammatory bowel disease
10/26/2010CA2498267C Method for treating erectile dysfunction and increasing libido in men
10/26/2010CA2487270C Antimicrobial compositions, products and methods employing same
1 ... 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 ... 7860